Role of NF-κB and cytokine in experimental cancer cachexia

Table 1 Clinical features of tumor-bearing and non-tumor-bearing mice

Group	Initial body wt(g)	Final body wt (g)	Nontumor body wt (g)	Gastrocnemius muscle wt (mg)	Dry food intake (g ··day -1)
Control	20.93 ± 1.40	25.50 ± 1.71	25.50 ± 1.71	136.8 ± 6.11	6.65 ± 0.24
Tumor + saline	20.91 ± 1.29	25.95 ± 1.61	20.92 ± 1.52a	97.5 ± 8.32a	6.53 ± 0.31
Tumor+IND(0.25 mg·kg-1)	20.98 ± 1.42	27.75 ± 2.20	21.75 ± 1.64	95.65 ± 13.5	6.56 ± 0.27
Tumor +IND(0.5 mg·kg-1)	20.92 ± 1.14	27.83 ± 1.88	22.48 ± 1.57	115.82 ± 9.63b	6.70 ± 0.32
Tumor +IND(2.0 mg·kg-1)	21.38 ± 1.00	28.00 ± 1.24	21.90 ± 1.38	93.15 ± 10.83	6.53 ± 0.19

^aP < 0.01, vs control;

^bP < 0.01, vs tumor + saline.

Table 2 Serum levels of TNF-α and IL-6 in mice

Parameter	Control	Tumor + saline	Tumor + IND(0.25mg ··kg-1)	Tumor+IND(0.5mg ··kg-1)	Tumor+IND(2.0mg ··kg-1)
TNF-α(pg/ml)	43.24 ± 13.37	113.83 ± 16.91a	89.9 ± 4.5	71.68 ± 16.70 b	110.96 ± 20.93
IL-6 (pg/ml)	1445.82 ± 244.20	2646.05 ± 93.39a	2527.78 ± 266.43	1983.07 ± 219.19 c	2733.33 ± 201.84

^aP < 0.01, vs control;

^bP < 0.05, vs tumor + saline;

^cP < 0.01, vs tumor + saline.